- Why early de-risking is redefining the path to INDLonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.Fierce Biotech · 12d ago↗ source
- Radiopharma maker AdvanCell hauls in $315M for Pluvicto challengerAdvanCell raised a $315 million Series D to study a lead-based prostate cancer agent and shore up its US manufacturing of the radioactive treatment. The round marks one of the largest yet for a r…Endpoints · 12d ago↗ source
- Understanding Agentic AI in Clinical DevelopmentEarlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an “AI strategy”, not because strategy doesn’t matter, but becaus…Fierce Biotech